Arovella Confirms Nicole Van Der Weerden As CEO; Shareholders Reject Option Ratification
ALA: $0.050 +0.00% · MC: $60M
Arovella Therapeutics confirmed Nicole Van Der Weerden’s appointment as Chief Executive Officer, correcting an earlier announcement that described her role as acting CEO. Shareholders carried nine of ten AGM resolutions, rejecting ratification of a prior options issue; Arovella shares rose around 6% on the day, alongside the updates.

Comments